Otsuka Pharmaceutical to Acquire Transcend Therapeutics

New Data Demonstrating the Mechanism of Action of TSND-201 (methylone) for the Treatment of PTSD Published in Neuropsychopharmacology

Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND- 201 (methylone) for the Treatment of PTSD

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

Transcend Therapeutics Presents New Data from the Open-Label Portion of the IMPACT-1 Study and Further Data Supporting the Neuroplasticity Mechanism of TSND-201

TSND-201 (Methylone) for the Treatment of PTSD: Improvements across each CAPS-5 Cluster and Anxiety Symptoms from the Open-Label Portion of the IMPACT-1 Study

TSND-201 (Methylone): A Rapid-Acting Neuroplastogen that Stimulates Neurite Outgrowth

Fierce Biotech: Psychiatry biotech hopes to Transcend PTSD rivals with new data

TSND-201 (methylone) for PTSD: Initial Results from Open-Label Study (IMPACT-1)

Transcend Therapeutics Announces Positive Open-Label Data from IMPACT-1

Methylone: Distinct Pharmacological and Mechanistic Effects Compared with MDMA

Transcend and Yale awarded U.S. Department of Defense grant to study methylone for PTSD